Identification of novel selective P2Y6 receptor antagonists by high-throughput screening assay

Life Sci. 2017 Jul 1:180:137-142. doi: 10.1016/j.lfs.2017.05.017. Epub 2017 May 17.

Abstract

Aims: The P2Y6 nucleotide receptor is widely involved in inflammatory responses, and is a promising molecular target for the treatment of inflammatory diseases. Although several P2Y6 receptor antagonists have been developed and evaluated thus far, none has successfully been developed into a therapeutic drug. In this study, we explored new promising compounds that inhibit the human P2Y6 receptor.

Main methods: High-throughput screening (HTS) was used to study the effects of various compounds on human P2Y6 receptors expressed in 1321N1 human astrocytoma cells by monitoring intracellular Ca2+ concentration ([Ca2+]i) levels using an FDSS7000 real-time fluorescence detector. IL-8 concentration was measured by enzyme-linked immunosorbent assay.

Key findings: Among structurally diverse chemical libraries totalling 141,700 compounds, 43 compounds with an inhibitory activity against the P2Y6 receptor were identified. Further studies using a dose-response assay, receptor selectivity assay, and chemokine measurement assay revealed the selective P2Y6 receptor inhibitor TIM-38, which inhibited UDP-induced [Ca2+]i elevation in a dose-dependent manner. TIM-38 had an IC50 value of 4.3μM and inhibited P2Y6 without affecting the response induced by four other human P2Y or muscarinic receptors. In addition, TIM-38 inhibited UDP-induced interleukin-8 release in a dose-dependent manner without affecting releases caused by other stimulus such as interleukin-1β or tumour necrosis factor-α. Analyses of TIM-38 derivatives revealed that the nitro moiety is vital to P2Y6 receptor inhibition.

Significance: TIM-38 acts as a novel structural antagonist of P2Y6 receptor and may be a good lead compound for developing a P2Y6 receptor-targeted anti-inflammatory drug.

Keywords: Compound 1 (6-bromo-3-nitro-2-(trifluoromethyl)-2H-chromene, PubChem CID: 11681366); Compound 2 (2-(4-chlorophenyl)-3-nitro-2H-chromene, PubChem CID: 3774501); Compound 3 (2-(4-methoxyphenyl)-3-nitro-2H-chromene, PubChem CID: 2732134); Compound 4 (3-nitro-2-phenyl-2H-chromene, PubChem CID: 42450); High-throughput screening; Interleukin-8; P2Y(6) receptor antagonist; TIM-38 (3-nitro-2-(trifluoromethyl)-2H-chromene, PubChem CID: 16762479).

MeSH terms

  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / chemistry
  • Anti-Inflammatory Agents / pharmacology*
  • Astrocytoma / metabolism
  • Calcium / metabolism
  • Cell Line, Tumor
  • Dose-Response Relationship, Drug
  • Drug Design*
  • Enzyme-Linked Immunosorbent Assay
  • High-Throughput Screening Assays / methods*
  • Humans
  • Inhibitory Concentration 50
  • Interleukin-1beta / metabolism
  • Interleukin-8 / metabolism
  • Purinergic P2Y Receptor Antagonists / administration & dosage
  • Purinergic P2Y Receptor Antagonists / chemistry
  • Purinergic P2Y Receptor Antagonists / pharmacology*
  • Receptors, Purinergic P2 / drug effects*
  • Receptors, Purinergic P2 / metabolism
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Anti-Inflammatory Agents
  • Interleukin-1beta
  • Interleukin-8
  • Purinergic P2Y Receptor Antagonists
  • Receptors, Purinergic P2
  • Tumor Necrosis Factor-alpha
  • purinoceptor P2Y6
  • Calcium